Active Implementation of an Evidence-Based Nutrition Guideline for Critically Ill Patients Versus Standard Care: A Cluster Randomised, Multicentre, Controlled Trial
Lu Ke,Jiajia Lin,Gordon S. Doig,Arthur R.H. van Zanten,Yang Wang,Juang Xing,Zhongheng Zhang,Tao Chen,Lixin Zhou,Dongpo Jiang,Qindong Shi,Jiandong Lin,Jun Liu,Aibin Cheng,Yafeng Liang,Peiyang Gao,Junli Sun,Wenming Liu,Zhenyu Yang,Rumin Zhang,Wei Xing,An Zhang,Zhigang Zhou,Tingfa Zhou,Yang Liu,Fei Tong,Qiuhui Wang,Aijun Pan,Xiaobo Huang,Chuming Fan,Weihua Lu,Dongwu Shi,Lei Wang,Wei Li,Liming Gu,Yingguang Xie,Rongqing Sun,Feng Guo,Lin Han,Lihua Zhou,Xiangde Zheng,Feng Shan,Jianbo Liu,Yuhang Ai,Yan Qu,Liandi Li,Hailing Li,Zhiguo Pan,Donglin Xu,Zhiqiang Zou,Yan Gao,Chunli Yang,Qiuye Kou,Xijing Zhang,Jinglan Wu,Chuanyun Qian,Weixing Zhang,Minjie Zhang,Yuan Zong,Bingyu Qin,Fusen Zhang,Zhe Zhai,Yun Sun,Ping Chang,Bo Yu,Min Yu,Shiying Yuan,YiJun Deng,Liyun Zhao,Bin Zang,Yuanfei Li,Fachun Zhou,Xiaomei Chen,Min Shao,Weidong Wu,Ming Wu,Zhaohui Zhang,Yimin Li,Qiang Guo,Zhiyong Wang,Yuanqi Gong,Yunlin Song,Kejian Qian,Yongjian Feng,Baocai Fu,Xueyan Liu,Zhiping Li,Chuanyong Gong,Cheng Sun,Jian Yu,Zhongzhi Tang,Linxi Huang,Biao Ma,Zhijie He,Qingshan Zhou,Rongguo Yu,Zhihui Tong,Weiqin Li
DOI: https://doi.org/10.2139/ssrn.3792190
2021-01-01
Abstract:Background: Equipoise exists regarding the implementation of evidence-based guidelines for nutritional therapy in critical illness because some previous cluster-randomised controlled trials (cRCTs) demonstrate patient benefits whilst others do not. We aimed to resolve this issue by initiating an appropriately powered cRCT to assess whether active implementation of an evidence-based guideline for nutrition therapy in critical illness could reduce mortality. Methods: We did a multicentre, cluster-randomised, parallel-controlled trial in 97 intensive care units (ICUs) throughout China. We developed an up-to-date, evidence-based nutrition guideline. ICUs randomly allocated to implement the guideline formed a local "intervention team", which actively implemented the guideline using standardized educational materials. ICUs assigned to the control group remained unaware of the guideline. All ICUs enroled critically ill patients who were expected to stay longer than seven days. The primary outcome was all-cause mortality within 28 days of enrolment . Findings Between March, 2018 and July, 2019, we enrolled 1,373 patients at 48 guideline ICUs and 1,399 patients at 49 control ICUs. Implementation of the nutrition guideline resulted in significantly earlier enteral nutrition (EN) initiation (1.20 vs. 1.55 mean days to initiation of EN; difference -0.40 [95% CI, -0.71 to -0.09]; P=0.01) and delayed parenteral nutrition (PN) initiation (1.29 vs. 0.80 mean days to start of PN; difference 1.06 [95% CI, 0.44 to 1.67]; P=0.001). There was no significant difference in 28-day mortality (14.2% vs. 15.2%; difference -1.6% [95% CI -4.3% to 1.2%]; p=0.42) between study groups. Interpretation: Active implementation of an evidence-based guideline can change practice. Our active implementation strategy improved the provision of nutrition therapy to critically ill patients. However, in our cRCT, this improvement in care did not translate to a reduction in mortality. We did not identify any safety concerns associated with the active implementation of our evidence-based guideline for nutrition therapy. Trial Registration: The study was registered in the ISRCTN registry before enrolment commenced (No. ISRCTN12233792). Funding Statement: The study was funded by the Key Research and Development Program Foundation of Jiangsu Province of China (no. BE2015685) and Nutricia, Wuxi, China. Declaration of Interests: Dr. GSD reported receiving academic research grants related to nutrition in critical illness from the Australian National Health and Medical Research Council, Fresenius Kabi Deutschland GmbH and Baxter Healthcare Pty Ltd and speakers honoraria from Fresenius Kabi Deutschland GmbH, Baxter Healthcare Australia, Pty Ltd, Nestle Healthcare, Vevy, Switzerland and Nutricia Pharmaceutical (Wuxi) Co., Ltd. China. Dr. AvZ reports personal fees from Baxter, personal fees from Nestle, personal fees from Fresenius Kabi, grants and personal fees from Nutricia, grants from Cardinal Health grants from Mermaid grants from Lyric, outside the submitted work. Dr. WqL reported receiving speakers honoraria from Nutricia Pharmaceutical (Wuxi) Co., Ltd. China. No other disclosures were reported. Ethics Approval Statement: The study was approved by the local hospital ethics committees of all the participating ICUs. At each site, informed consent was obtained from the patients or their next of kin before enrolment.